Company intelligence / Profile preview

Torpedo Pharmaceuticals

Ownership: Private
Development stage: Preclinical

Overview

Torpedo Pharmaceuticals is developing next-generation radiopharmaceuticals using Terbium‑161, with preclinical data showing superior efficacy and safety compared to current standards like Lutetium‑177. Early clinical data in a small patient cohort demonstrated partial responses or stable disease after a single dose. The company is advancing toward broader clinical development targeting multiple solid tumor indications.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalRadioligand therapySmall molecule
Industry: Biotech

Drug pipeline

1 asset

¹⁶¹Tb-PSMA-617

Unknown

Partnerships

Academic institutions for technology developmentIndustrial partners for technology developmentIndustrial partners for supply chain of Terbium‑161

Beyond the preview

Go deeper on Torpedo Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Torpedo Pharmaceuticals.

Explore the full profile